Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alcon AG (ALC) vs Linde PLC (LIN) Price & Performance

Alcon AG
Linde PLC

Price performance

Price movement over the last 24 hours

Key statistics

Alcon AG vs Linde PLC — how do they compare? Alcon AG trades at $66.96 (market cap $32.69B), while Linde PLC trades at $529.85 (market cap $248.85B). The key difference: Linde PLC is far larger — about 7.6× Alcon AG's market cap, and Linde PLC pays the higher dividend (1.19%). Which is the better fit depends on your goals.

ALCLIN
Market Cap
$32.69B$248.85B
Sector
HealthBasic Materials
52-Week High
$92.22$546.64
52-Week Low
$62.02$389.38
Enterprise Value
$36.28B$271.21B
Dividend Yield
0.54%1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alcon AG

ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.

The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.

Linde PLC

Linde (LIN) trades at $540.52, down 1.12% on the day, with a bullish technical outlook supported by moving averages and key resistance at $546. The company reported strong Q1 2026 EPS of $4.33, beating estimates, and maintains robust profitability with a 20.44% net income margin. Recent news highlights sustainability leadership and strategic growth, while cash flow remains positive despite projected 2026 outflows.

Outlook remains positive with 85.7% analyst buy ratings and a $570.80 consensus price target, suggesting 5.6% upside. Risks include rising debt-to-asset ratio (31.63% in 2025) and valuation concerns (P/E 35.84). The stock offers a dividend yield of approximately 0.3% with consistent shareholder returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alcon AG

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.

Read more on ALC

About Linde PLC

Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.

Read more on LIN